Is NCT04623931 recruiting in Houston, TX?

Yes, NCT04623931 is currently recruiting participants at its Houston, TX location. This anaplastic astrocytoma, idh-wildtype clinical trial is actively enrolling qualified participants.

Is participation in this Houston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Anaplastic Astrocytoma, IDH-Wildtype Clinical Trial in Houston, TX

Q: How do I join the anaplastic astrocytoma, idh-wildtype clinical trial in Houston?

To join this clinical trial in Houston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Anaplastic Astrocytoma, IDH-Wildtype Study in Houston

This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The goal of this clinical research study is to compare receiving new radiation therapy doses and volumes to the prior standard treatment for patients with historically grade II or grade III IDH wild-type gliomas, which may now be referred to as IDH wildtype molecular glioblastomas at some institutions. Receiving temozolomide in combination with radiation therapy may also help to control the disease.

Sponsor: M.D. Anderson Cancer Center

Who Can Participate

Inclusion Criteria

Historical grade II and III gliomas IDH wildtype gliomas by including; diffuse astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, anaplastic oligoastrocytoma

IDH wildtype gliomas (molecularly defined high grade glioma or molecularly defined glioblastoma \[GBM\])

History \& physical exam, and Karnofsky performance status (KFS) of \>= 70 within 30 days prior to enrollment

Post-operative magnetic resonance imaging (MRI) with contrast is mandatory and necessary for radiation therapy (RT) planning

Thin-slice (\< 1.5 mm) three-dimensional (3D) T1 pre and post contrast and axial T2/fluid-attenuated inversion recovery (FLAIR) sequences for planning purposes are highly encouraged to obtain.

Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 (within 60 days prior to registration)

Platelets \>= 100,000 cells/mm\^3 (within 60 days prior to registration)

Hemoglobin \>= 10.0 g/dl (within 60 days prior to registration) (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 10.0 g/dl is acceptable)

Bilirubin =\< 1.5 upper limit of normal (ULN) (within 60 days prior to registration)

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN (within 60 days prior to registration)

Blood urea nitrogen (BUN) \< 30 mg/dl (within 60 days prior to registration)

Serum creatinine \< 1.5 mg/dl (within 60 days prior to registration)

Exclusion Criteria

Definitive clinical or radiologic evidence of metastatic disease; if applicable

Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years. (For example, carcinoma in situ of the breast, oral cavity or cervix are permissible)

Prior cranial radiotherapy or radiotherapy to the head and neck where potential field overlaps would exist

Prior chemotherapy or radiotherapy for any brain tumor

Histologic diagnosis of gliosarcoma World Health Organization (WHO grade IV) or pilocytic astrocytoma (WHO grade I)

Multicentric glioblastoma

Leptomeningeal disease

Inability to undergo MRI with and without contrast

Severe, active co-morbidity defined as follows:

Unstable angina or congestive heart failure requiring hospitalization within 6 months prior to enrollment

Transmural myocardial infarction within the last 6 months prior to registration. Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of \>= 2 mm using the analysis of an electrocardiogram (EKG) performed within 28 days prior to registration. (Note: EKG to be performed only if clinical suspicion of cardiac issue) • New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to registration

Serious and inadequately controlled arrhythmia at step 2 registration

Serious or non-healing wound, ulcer or bone fracture or history of abdominal fistula, intra-abdominal abscess requiring major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to registration, with the exception of the craniotomy for surgical resection

Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol

Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration

Human immunodeficiency virus (HIV) positive with CD4 count \< 200 cells/microliter. Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is because the treatments involved in this protocol may be significantly immunosuppressive with potentially fatal outcomes in patients already immunosuppressed

Any other severe immunocompromised condition

Active connective tissue disorders, such as lupus or scleroderma that in the opinion of the treating physician may put the patient at high risk for radiation toxicity

End-stage renal disease (i.e., on dialysis or dialysis has been recommended)

Any other major medical illnesses or psychiatric treatments that in the investigator's opinion will prevent administration or completion of protocol therapy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT04623931) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Anaplastic Astrocytoma, IDH-Wildtype Treatment Options in Houston, TX

If you're searching for anaplastic astrocytoma, idh-wildtype treatment options in Houston, TX, this clinical trial (NCT04623931) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced anaplastic astrocytoma, idh-wildtype specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all anaplastic astrocytoma, idh-wildtype clinical trials near you to find additional studies recruiting in your area.

Anaplastic Astrocytoma, IDH-Wildtype Clinical Trial in Houston, TX

Expert Care in Houston

IRB Approved

No-Cost Care

Apply for This Houston Location

Why Participate?

Simple Process